Meeting
2018 ASCO Quality Care Symposium
Treatment patterns, toxicity, and outcomes of elderly patients with advanced pancreatic cancer receiving first-line chemotherapy.
Authors
Robert Kudlovich
University of Mantioba, Winnipeg, MB, Canada
Robert Kudlovich, Hanbo Zhang, Christina Kim, David Dawe
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Big Data Studies; Projects Relating to Equity, Value, and Policy
Track
Projects Relating to Equity, Value and Policy,Big Data Studies
Sub Track
Health Disparities
Citation
J Clin Oncol 36, 2018 (suppl 30; abstr 71)
DOI
10.1200/JCO.2018.36.30_suppl.71
Abstract #
71
Poster Bd #
G12
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Use of first-line chemotherapy for advanced pancreatic cancer: FOLFIRINOX versus gemcitabine-based therapy.
First Author: Thomas H. Cartwright
Poster
2013 ASCO Annual Meeting
Updated use of first-line chemotherapy for advanced pancreatic cancer: Folfirinox versus gemcitabine.
First Author: Thomas H. Cartwright
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Efficacy of the third-line chemotherapy in patients with advanced pancreatic cancer.
First Author: Bomi Kim
Poster
2020 ASCO Virtual Scientific Program
HGCSG 1803: Single-arm phase II study evaluating efficacy of oxaliplatin, irinotecan and S-1 combination therapy (OX-IRIS) in metastatic pancreatic cancer as first-line treatment.
First Author: Shintaro Nakano